tbuckley/cabot-search huggingface dataset:
Alternative polyadenylation factors link cell cycle to migration
Authors: Mithun Mitra, Elizabeth L Johnson, Vinay S Swamy, Lois E Nersesian, David C Corney, David G Robinson, Daniel G Taylor, Aaron M Ambrus, David Jelinek, Wei Wang, Sandra L Batista, Hilary A Coller
Journal: Genome biology (2018)

In response to a wound, fibroblasts are activated to migrate toward the wound, to proliferate and to contribute to the wound healing process. We hypothesize that changes in pre-mRNA processing occurring as fibroblasts enter the proliferative cell cycle are also important for promoting their migration. RNA sequencing of fibroblasts induced into quiescence by contact inhibition reveals downregulation of genes involved in mRNA processing, including splicing and cleavage and polyadenylation factors. These genes also show differential exon use, especially increased intron retention in quiescent fibroblasts compared to proliferating fibroblasts. Mapping the 3′ ends of transcripts reveals that longer transcripts from distal polyadenylation sites are more prevalent in quiescent fibroblasts and are associated with increased expression and transcript stabilization based on genome-wide transcript decay analysis. Analysis of dermal excisional wounds in mice reveals that proliferating cells adjacent to wounds express higher levels of cleavage and polyadenylation factors than quiescent fibroblasts in unwounded skin. Quiescent fibroblasts contain reduced levels of the cleavage and polyadenylation factor CstF-64. CstF-64 knockdown recapitulates changes in isoform selection and gene expression associated with quiescence, and results in slower migration. Our findings support cleavage and polyadenylation factors as a link between cellular proliferation state and migration.
Extreme Lewontin’s Paradox in Ubiquitous Marine Phytoplankton Species
Authors: Dmitry A Filatov
Journal: Molecular Biology and Evolution (2018)

Larger populations are expected to have larger genetic diversity. However, as pointed out by Lewontin in 1974, the range of population sizes exceeds the range of genetic diversity by many orders of magnitude (a.k.a. "Lewontin's paradox," LP). The reasons for LP remain obscure. Here, This paper reports an extreme case of LP in astronomically large populations of the ubiquitous unicellular marine phytoplankton species Emiliania huxleyi (Haptophyta)-the species that accounts for 10-20% of primary productivity in the oceans and its blooms are so extensive that they are visible from space. This study demonstrates that despite the wide distribution and enormous population size, the world-wide sample of E. huxleyi strains with sequenced genomes represents a single cohesive species and contains surprisingly limited genetic diversity (π ∼ 0.006 per silent site). The patterns of polymorphism reveal even larger populations in the past, and frequent recombination (ρ ∼ 0.006) throughout the genome, ruling out demographic history and asexual reproduction as possible causes of low polymorphism in E. huxleyi. Natural selection wiping out genetic diversity at linked sites (a.k.a. "genetic draft") must be strong and frequent to account for low polymorphism in E. huxleyi. This study sheds the first light on poorly understood evolutionary genetic processes in astronomically large populations of marine microplankton.
RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration
Authors: Jeffrey W. Hofmann, William W. Seeley, Eric J. Huang
Journal: Annual Review of Pathology Mechanisms of Disease (2018)

Frontotemporal dementia is a group of early onset dementia syndromes linked to underlying frontotemporal lobar degeneration (FTLD) pathology that can be classified based on the formation of abnormal protein aggregates involving tau and two RNA binding proteins, TDP-43 and FUS. Although elucidation of the mechanisms leading to FTLD pathology is in progress, recent advances in genetics and neuropathology indicate that a majority of FTLD cases with proteinopathy involving RNA binding proteins show highly congruent genotype–phenotype correlations. Specifically, recent studies have uncovered the unique properties of the low-complexity domains in RNA binding proteins that can facilitate liquid–liquid phase separation in the formation of membraneless organelles. Furthermore, there is compelling evidence that mutations in FTLD genes lead to dysfunction in diverse cellular pathways that converge on the endolysosomal pathway, autophagy, and neuroinflammation. Together, these results provide key mechanistic insights into the pathogenesis and potential therapeutic targets of FTLD.
Distinct clinico-pathological features of hypermutant colorectal cancers with POLE pathogenic mutations, Lynch syndrome and sporadic MSI analyzed over 1,000 colorectal cancer patients
Authors: T. Nagasaka, A. Nyuya, H. Tanioka, Y. Katata, M. Yokota, F. Taniguchi, T. Kawai, Y. Mori, K. Shigeyasu, M. Okawaki, M. Yamamura, Y. Umeda, A. Tsuruta, T. Ueno, Y. Yamaguchi
Journal: Annals of Oncology (2018)
Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti–PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer
Authors: C. Drescher, K.N. Moore, J.F. Liu, D.M. O’Malley, E.W. Wang, J.S.-Z. Wang, V. Subbiah, B.A. Wilky, G. Yuan, C.D. Dupont, A.M. Gonzalez, D. Savitsky, S. Coulter, O. Shebanova, E. Dow, W. Ortuzar, J.S. Buell, R.B. Stein, H. Youssoufian
Journal: Annals of Oncology (2018)
P1.13-29 Overall Response Rate of Nintedanib and Docetaxel in Combination with the Nutraceutical Use of Silibinin in Advanced NSCLC
Authors: J. Bosch Barrera, J.C. Ruffinelli, E. Carcereny, E. Sais, S. Verdura, E. Cuyàs, R. Palmero, A. Izquierdo, T. Morán, E. Nadal, J.A. Menéndez
Journal: Journal of Thoracic Oncology (2018)
Pharmacokinetic/pharmacodynamic relationship of enzalutamide and its active metabolite N-desmethyl enzalutamide in metastatic castration-resistant prostate cancer patients
Authors: M.-L. Joulia, E. Carton Vienet Legue, M. Allard, O. Huillard, M. Peyromaure, M. Zerbib, M. Vidal, F. Goldwasser, J. Alexandre, B. Blanchet
Journal: Annals of Oncology (2018)
P3.01-30 Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan
Authors: Y. Goto, N. Yamamoto, E. Masters, H. Kikkawa, J. Mardekian, R. Wiltshire, K. Togo, H. Ma, Y. Ohe
Journal: Journal of Thoracic Oncology (2018)
P1.13-01 Anti-EGF Antibodies Increase the Effect of ALK and MEK Inhibitors in ALK and KRAS NSCLC and CRC Cell Lines
Authors: S. Garcia – Roman, J. Codony-Servat, M. Molina-Vila, J. Bertran-Alamillo, A. Giménez-Capitán, S. Viteri, A. Cardona, D. Rodríguez-Abreu, M. Cobo Dols, N. Reguart, N. Karachaliou, E. D'Hondt, R. Rosell
Journal: Journal of Thoracic Oncology (2018)
P2.11-29 Impact of an Information-Film to Promote Informed Decision-Making in Individuals Taking Part in a Lung Cancer Screening Demonstration Pilot
Authors: M. Ruparel, S. Quaife, B. Ghimire, J. Dickson, C. Horst, S. Tisi, A. Bhowmik, N. Navani, D. Baldwin, S. Duffy, J. Waller, S. Janes
Journal: Journal of Thoracic Oncology (2018)
P1.17-02 Low Prognostic Nutritional Index Predicts Poor Survival in Stage IIIB Non-Small Cell Lung Cancer Patients Treated with Chemoradiotherapy
Authors: A. Besen, E. Topkan, Y. Ozdemir, O. Guler, B. Yıldırım, U. Selek, F. Kose, O. Ozyılkan
Journal: Journal of Thoracic Oncology (2018)
P2.01-53 Local Treatment for Oligoprogression/Oligometastases After Failure to Crizotinib for ALK-Rearranged Stage IV Lung Cancer
Authors: T.Y. Kam, J. Li, M.y. Lim, O.S.h. Chan, K.c. Cheung, V. Lee
Journal: Journal of Thoracic Oncology (2018)
Intraperitoneal chemotherapy (IP CT) after cytoreductive surgery benefits survival in epithelial ovarian cancer (EOC): Results of a pooled meta-analysis including 9 randomized clinical trials (RCT)
Authors: M. Jimenez-Heredia, J.A. Perez Fidalgo, M. Morales Suarez-Varela, J. Sanchis, M. Aranda, A. Cervantes
Journal: Annals of Oncology (2018)
Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition
Authors: D. Basile, S.K. Garattini, G. Pelizzari, F. Cortiula, L. Gerratana, M. Cattaneo, C. Corvaja, A. Parnofiello, V.J. Andreotti, E. Bertoli, C. Lisanti, D. Iacono, M. Casagrande, G.G. Cardellino, G. Miolo, N. Pella, G. Aprile, A. Buonadonna, G. Fasola, F. Puglisi
Journal: Annals of Oncology (2018)
Trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of prior use of antiangiogenics: First results of an observational, prospective study
Authors: S. Pignata, G. Scambia, T. Mazzei, M. Arruti Barbia, E. Naglieri, L.M. de Sande
Journal: Annals of Oncology (2018)
P2.15-29 Eligibility for Anti-Angiogenic Treatments in Patients with Squamous Non-Small Cell Lung Cancer (SQ-NSCLC): EPISQUAMAB Study (GFPC 2015-01)
Authors: A. Vergnenegre, V. Basse, G. Le Garff, O. Bylicki, C. Dubos-Arvis, B. Comet, M. Marcq, J. Le Treut, J.B. Auliac, A. Madroszyk, G. Fraboulet, J. Crequit, P. Thomas, N. Paleiron, I. Monnet
Journal: Journal of Thoracic Oncology (2018)
P1.09-36 Clinical Significance of Cannabinoid Receptor CB2 Expression in Non Small Cell Lung Cancer (NSCLC)
Authors: N. Tsoukalas, C. Giaginis, P. Alexandrou, M. Tolia, I. Binas, P. Baxevanos, E. Aravantinou, K. Tsapakidis, M. Galanopoulos, M. Kiakou, I. Zerdes, I. Kostakis, I. Litos, M. Liontos, E. Tsiambas, I. Sfiniadakis, G. Kyrgias, N. Kavantzas, E. Patsouris, S. Theocharis
Journal: Journal of Thoracic Oncology (2018)
Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors
Authors: N.M. Tannir, A. Naing, K.P. Papadopoulos, D.J. Wong, W.M. Korn, R. Aljumaily, K.A. Autio, S. Pant, T.M. Bauer, A. Drakaki, N. Daver, A. Hung, M. Oft, J. Leveque
Journal: Annals of Oncology (2018)
Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis: a randomised, double-blinded, sham-controlled trial
Authors: Elien A M Mahler, Michiel JM Minten, Mathilde M Leseman-Hoogenboom, Philip M P Poortmans, Jan Willem H Leer, Simone S Boks, Frank H J van den Hoogen, Alfons A den Broeder, Cornelia H M van den Ende
Journal: Annals of the Rheumatic Diseases (2018)

Objectives Low-dose radiation therapy (LDRT) for benign disorders such as knee osteoarthritis (OA) is widely used in some parts of the world, despite absence of controlled studies. We evaluated the effect of LDRT on symptoms and inflammation in patients with knee OA. Methods In this randomised, double-blinded, sham-controlled clinical trial (RCT), we recruited patients with knee OA (clinical ACR criteria) in the Netherlands, aged ≥50 years, pain score ≥5/10 and non-responding to analgesics and exercise therapy. Patients were randomised 1:1 to receive LDRT (1 Gray per fraction) or sham intervention six times in 2 weeks, stratified by pain (&lt;8 versus ≥8/10). Primary outcome was the proportion of OMERACT-OARSI responders, 3 months postintervention. Secondary outcomes included pain, function and inflammatory signs assessed by ultrasound, MRI and serum inflammatory markers. Results We randomly assigned 55 patients: 27 (49%) to LDRT and 28 (51%) to sham. At 3 months postintervention, 12/27 patients (44%; 95% CI 26% to 63%) in the LDRT vs 12/28 patients (43%; 95% CI 25% to 61%) in the sham group responded; difference 2% (95% CI 25% to 28%), OR adjusted for the stratifying variable was 1.1 (95% CI 0.4 to 3.2). Also, for clinical and any of the inflammatory signs, no differences were observed. Conclusions We found no substantial beneficial effect on symptoms and inflammatory signs of LDRT in patients knee OA, compared with sham treatment. Therefore, based on this RCT and the absence of other high-quality evidence, we advise against the use of LDRT as treatment for knee OA. Trial registration number NTR4574.
Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A)
Authors: J.R. Diamond, N. Standifer, M.L. Ascierto, C. Morehouse, H. Ghadially, J. Rodriguez Canales, M.C. Rebelatto, J. Naidoo, L. Mazzarella, S. Patel, M.J. Flor Oncala, T. Alonso Gordoa, D. Wang, X. Song, D.C. Jones, X. Li, S. Marshall, S. Abdullah, M. Jure-Kunkel, M.D. Hellmann
Journal: Annals of Oncology (2018)
Clinical characterization of rare EGFR mutations in non-small cell lung cancer and in silico prediction of drug sensitivity
Authors: S. Ikemura, H. Yasuda, S. Matsumoto, M. Kamada, T. Betsuyaku, Y. Okuno, K. Goto, K. Tsuchihara, K. Soejima
Journal: Annals of Oncology (2018)
Effective chemical virus inactivation of patient serum compatible with accurate serodiagnosis of infections
Authors: M.M. Remy, M. Alfter, M.-N. Chiem, M.T. Barbani, O.B. Engler, F. Suter-Riniker
Journal: Clinical Microbiology and Infection (2018)

ObjectivesHighly pathogenic viruses such as EBOV are a threat to routine laboratory workers. Inactivation procedures with Triton X-100 0.1% and/or heat are currently recommended, but have unknown effects on the accuracy of serological testing. Furthermore, virus inactivation by Triton X-100 0.1% was shown to be ineffective in serum. This study aimed to demonstrate virus inactivation in serum by Triton X-100 1% and maintained accuracy of serological testing.MethodsA panel of 19 serological tests was run on patient serum samples after treatment with Triton X-100 1%, 0.1%, and 0.1% + heat inactivation at 60°C for 1 h. Mean differences between measurements (bias) were calculated applying the Bland–Altman method. To determine effectiveness of virus inactivation, herpes simplex virus 1 (HSV-1) was spiked into medium containing 90% or 1% serum, and treated with Triton X-100 0.1% or 1%. Infectious titres were then determined on Vero cells.ResultsSerological measurements showed good agreement between controls and samples treated with Triton X-100 0.1% and 1%, with an estimated bias of 0.6 ± 9.2% (n = 258) and –0.1 ± 18.6% (n = 174), respectively. Discordant qualitative results were rare. Conversely, heat inactivation alone and combined with Triton X-100 0.1% triggered a bias of 17.5 ± 66.4% (n = 200) and 37.9 ± 79.8% (n = 160), respectively. Triton X-100 1% completely inactivated HSV-1 in 1% and 90% serum while Triton X-100 0.1% failed to do so in 90% serum.ConclusionsUnlike heat inactivation, Triton X-100 1% enabled accurate serological testing and completely inactivated HSV-1 in serum. This simple method could allow safe routine serological diagnostics in high-risk patients.
P1.05-14 Autofluorescence Mode of Thoracoscope Improves Visceral Pleural Invasion Diagnosis in Non-Small Cell Lung Cancer
Authors: H. Takizawa, T. Sawada, M. Takashima, D. Matsumoto, N. Kawakita, M. Tsuboi, H. Toba, M. Yoshida, Y. Kawakami, K. Kondo, A. Tangoku
Journal: Journal of Thoracic Oncology (2018)
Symptomatic skeletal related events (SSE) and SSE-free-survival in real world castration-resistant prostate cancer (CRPC) patients: Results from CAPRI
Authors: M. Kuppen, H.M. Westgeest, A.J.M. van den Eertwegh, J. Van Moorselaar, N. Mehra, I. van Oort, A.C.M. van den Bergh, J.L. Coenen, K.K.H. Aben, R. Somford, J. Lavalaye, A. Bergman, C.A. Uyl-de Groot, W.R. Gerritsen
Journal: Annals of Oncology (2018)
P2.13-14 The Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy
Authors: A. Szpechcinski, K. Duk, M. Bryl, G. Czyzewicz, E. Wojda, M. Florczuk, P. Sliwinski, A. Barinow-Wojewodzki, J. Chorostowska-Wynimko
Journal: Journal of Thoracic Oncology (2018)
OA08.07 In Silico Discovery of Unannotated miRNAs in Malignant Pleural Mesothelioma Reveals Novel Tissue-of-Origin Markers
Authors: B. Minatel, E. Marshall, C. Anderson, K. Ng, K. Enfield, A. Sage, Z. Xu, W. Lam, V. Martinez
Journal: Journal of Thoracic Oncology (2018)
P1.01-44 Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced NSCLC Patients: A Single-Centre Retrospective Analysis
Authors: S. Kate, A. Choughule, A. Joshi, V. Noronha, V. Patil, R. Dusane, P. Tiwrekar, L. Solanki, V. Trivedi, K. Prabhash
Journal: Journal of Thoracic Oncology (2018)
Effects of recombinant human PH20 (rHuPH20) on interstitial matrices: creating a favorable environment for the delivery of cytostatic agents
Authors: Ping Jiang, Anthony Hofer, Michael Haller, Gilbert A. Keller, Christian Brekken, Louis H. Bookbinder, Gregory I. Frost
Journal: Cancer Research (2005)

5075  Many tumors are associated with elevated levels of hyaluronan (HA). Through interaction with other extracellular matrix molecules, HA perturbs the delivery of cytostatic agents. Bovine forms of hyaluronidase, an HA degrading enzyme, have shown promise clinically as a chemosensitizing agent in a number of malignancies, but suffered immunologic and pharmacokinetic limitations. We therefore engineered a recombinant soluble form of human hyaluronidase (rHuPH20). The highly purified rHuPH20 enzyme lacked any gross or histologic toxicity across a very broad therapeutic range, and failed to elicit neutralizing antibodies in non human primates. rHuPH20 enhanced the dispersion of molecules up to 200nm in diameter in a dose dependent fashion, and increased hydraulic conductivity over 10 fold. These effects were fully reversible within 24 hours post injection. The enzyme itself was also systemically bioavailable, facilitating the dispersion of indicator dyes injected at distal sites without altering vascular permeability. Application of rHuPH20 to tumor cells in vitro effectively removed pericellular hyaluronan, which rapidly regenerated upon its removal from the culture media. Application of rHuPH20 to human xenograft models resulted in a significant reduction in tumor interstitial fluid pressure within 1 hour of administration. As increased interstitial fluid pressure is a key factor limiting bulk fluid flow in solid tumors, we conclude that recombinant human PH20 warrants testing as an adjunct to increase the therapeutic index of cytostatic regimens.
P2.01-81 Treatment of Superior Sulcus Tumor: A Twelve-Year Single-Center Experience
Authors: W. Rzyman, M. Lazar-Poniatowska, M. Lapinski, M. Ostrowski, A. Wrona, K. Konopa, J. Jassem, R. Dziadziuszko
Journal: Journal of Thoracic Oncology (2018)
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Authors: Diwakar Davar, Hong Wang, Joe-Marc Chauvin, Ornella Pagliano, Julien J. Fourcade, Mignane Ka, Carmine Menna, Amy Rose, Cindy Sander, Amir A. Borhani, Arivarasan Karunamurthy, Ahmad A. Tarhini, Hussein A. Tawbi, Qing Zhao, Blanca H. Moreno, Scott Ebbinghaus, Nageatte Ibrahim, John M. Kirkwood, Hassane M. Zarour
Journal: Journal of Clinical Oncology (2018)

Objective responses are reported in 34% to 37% of patients with programmed death-1 (PD-1)-naïve advanced melanoma treated with PD-1 inhibitors. Pre-existing CD8+ T-cell infiltrate and interferon (IFN) gene signature correlate with response to PD-1 blockade. Here, we report a phase Ib/II study of pembrolizumab/pegylated (PEG)-IFN combination in PD-1-naïve advanced melanoma.
Influenza vaccine effectiveness among cancer patients: A population-based study using health administrative and laboratory testing data from Ontario, Canada
Authors: P. Blanchette, H. Chung, K.I. Pritchard, C. Earle, M. Campitelli, N. Crowcroft, J. Gubbay, T. Karnauchow, K. Katz, A. McGeer, D. McNally, D. Richardson, S. Richardson, L. Rosella, A. Simor, M. Smieja, G. Zahariadis, A. Campigotto, J. Kwong
Journal: Annals of Oncology (2018)
Mutational landscape of metastatic cancers discovered from prospective clinical sequencing at community practice cancer program
Authors: R.H. Alvarez, A. Moran, E. Meiri, A. Loaiza-Bonilla, A.R. Parikh, P. Crilley, J. Elvin, P. Reddy, V.A. Miller, S. Zook, S.M. Ali, M. Markman
Journal: Annals of Oncology (2018)
P2.01-78 Validation of InVisionFirst ctDNA NGS Profiling via ddPCR Testing in Patients with Non-Small Cell Lung Cancer (NSCLC)
Authors: M. Pritchett, K. Baker-Neblett, K. Mileham, V. Plagnol, K. Howarth, T. Forshew, G. Jones, C. Morris
Journal: Journal of Thoracic Oncology (2018)
Prospective observational study to evaluate the persistence of treatment with denosumab (dmab) in patients (pts) with bone metastases (BM) from solid tumors (ST) in routine clinical practice: Final analysis
Authors: F. Haslbauer, A.L. Petzer, M. Safanda, A. Tomova, M. Porubska, Z. Bajory, D. Niepel, C. Jäger, D. Kalinin, R. Greil
Journal: Annals of Oncology (2018)
Nutritional support dependence after curative chemoradiotherapy in head and neck cancer: A supplementary analysis of a phase II trial (JCOG0706S1)
Authors: Y. Imamura, N. Kiyota, T. Akimoto, G. Ogawa, J. Eba, S. Minami, Y. Hasegawa, S. Iwae, N. Monden, K. Matsuura, H. Fujii, Y. Onozawa, A. Homma, R. Hayashi, M. Tahara
Journal: Annals of Oncology (2018)
Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low
Authors: M.E. Salem, A. Puccini, A. Grothey, J. Xiu, R. Goldberg, E.S. Kim, W.M. Korn, H.-J. Lenz, D. Raghavan, J.L. Marshall, M.J. Hall
Journal: Annals of Oncology (2018)
Moxetumomab Pasudotox: First Global Approval
Authors: Sohita Dhillon
Journal: Drugs (2018)

Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has been developed by MedImmune and its parent company AstraZeneca for the treatment of hairy cell leukaemia. The product, discovered at the National Cancer Institute, is an optimised version of immunotoxin CAT-3888. Moxetumomab pasudotox is composed of the Fv fragment of an anti-CD22 monoclonal antibody fused to a 38 kDa fragment of Pseudomonas exotoxin A, PE38. The Fv portion of moxetumomab pasudotox binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells, thereby delivering the toxin moiety PE38 directly to tumour cells. Once internalised, PE38 catalyses the ADP ribosylation of the diphthamide residue in elongation factor-2 (EF-2), resulting in the rapid fall in levels of the anti-apoptotic protein myeloid cell leukaemia 1 (Mcl-1), leading to apoptotic cell death. This article summarizes the milestones in the development of moxetumomab pasudotox leading to this first approval for the treatment of adults with relapsed or refractory hairy cell leukaemia who received at least two prior systemic therapies, including treatment with a purine nucleoside analogue. Development of moxetumomab pasudotox for non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and precursor cell lymphoblastic leukaemia/lymphoma was discontinued.
Prolonged survival (SV) associated with pulmonary metastasectomy (PM) for carcinomas of the cervix (CC)
Authors: J.F. Corona-Cruz, A. Castillo-Castañon, C.Z. Deneken, L.A. Ramirez-Tirado, A. Gonzalez-Enciso, D. Gallardo-Rincon, E. Jimenez-Fuentes, O. Arrieta
Journal: Annals of Oncology (2018)
Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial
Authors: J. Korach, G. Freyer, S. Banerjee, R. Asher, J. Cosin, A.M. Oza, A.M. Poveda, M. Di Napoli, C. Scott, M. Lapresa, F. Heitz, K. Takehara, G.S. Sonke, S. Tjulandin, J.-W. Kim, R. Hegg, I.B. Vergote, S. Turner, E. Pujade-Lauraine
Journal: Annals of Oncology (2018)
Advantages of next-generation sequencing in revealing low-level somatic mosaicism in blood samples of retinoblastoma patients
Authors: E.A. Alekseeva, V.M. Kozlova, T.L. Ushakova, A.S. Tanas, O.V. Babenko, T.P. Kazubskaya, V.V. Strelnikov, D.V. Zaletaev
Journal: Annals of Oncology (2018)
Phase Ib study of safety and tolerability of selinexor in Asian patients with advanced solid cancers
Authors: V.Y.M. Heong, M.L. Goh, W.P. Yong, R.A. Soo, C.E. Chee, S. Raghav, B.-C. Goh, S.C. Lee, J. Lim, A. Wong, D.S.P. Tan
Journal: Annals of Oncology (2018)
Clinical utility of plasma cell-free DNA in patients with pancreatic cancer
Authors: I. Chen, K.L. Wind, C. Dehlendorff, B.S. Sørensen, B.V. Vittrup, A. Johansen, P. Pfeiffer, J.K. Bjerregaard, S.E. Bojesen, S.E. Nielsen, N.H. Holländer, M.K. Yilmaz, L.S. Rasmussen, N. Pallisgaard, J.S. Johansen, K.-L.G. Spindler
Journal: Annals of Oncology (2018)